Cargando...
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
PURPOSE OF REVIEW: Although hypomethylating agents (HMAs) significantly improve outcomes in myelodysplastic syndromes (MDS), only half the patients achieve objective responses, and most responders lose response within 1–2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure o...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4124617/ https://ncbi.nlm.nih.gov/pubmed/24335709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOH.0000000000000016 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|